Partners hope to “chart a new era of drug discovery”

Big genomic data

A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments. 

In this partnership, M2GEN will license its real-world data set (RWD) to Zephyr AI, while Zephyr AI will become a bioinformatics partner for M2GEN, providing the company with AI and machine learning capabilities. 

“Cancer accounts for approximately one in six deaths globally. Even more troubling, by 2040, cancer is projected to claim an estimated 16.3 million lives around the world,” said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. “This partnership not only holds the potential to chart a new era of drug discovery and precision medicine, but to save innumerable lives.” 

M2GEN has lifetime, patient-consented longitudinal clinical data from more than 350,000 patients, coupled with whole exome (WES) and whole transcriptome (WTS) sequencing, for both tumour and germline data. The data will be integrated into Zephyr’s trademark Vulnerability Network Method, which uses algorithms to classify tumours and reveal new targets for drug discovery, label expansion, and precision care. 

“Collaboration is core to everything we do at M2GEN, and this opportunity symbolises the power of working in concert to accelerate the development of cancer treatments and cures,” said Jim Gabriele, CEO of M2GEN.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free